EHA 2017 | How can we manage CLL without worsening patients’ quality of life?
Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from St James’s University Hospital Leeds, Leeds, UK, discusses the management of chronic lymphocytic leukemia (CLL), particularly in patients who develop tolerability to novel drugs, such as ibrutinib and venetoclax. One suggestion made by Prof. Hillmen is the notion to reduce drug doses rather than stop treatment completely to maintain the clinical benefit of drugs whilst reducing their levels of toxicity in patients. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
Get great new content delivered to your inboxSign up